Vistagen Therapeutics (VTGN) Cash & Equivalents (2011 - 2026)

Vistagen Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $30.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 54.14% year-over-year to $30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.8 million (down 54.14% YoY) and the FY2026 annual result came in at $30.8 million, down 54.14% from the prior year.
• Cash & Equivalents fell to $30.8 million in Q1 2026 per VTGN's latest filing, from $47.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $126.6 million in Q4 2023 and troughed at $9.6 million in Q2 2023.
• A 5-year average of $59.4 million and a median of $52.0 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 81.53% in 2023, then surged 972.06% in 2024.
• Over 5 years, Cash & Equivalents stood at $25.0 million in 2022, then jumped by 406.4% to $126.6 million in 2023, then sank by 40.98% to $74.7 million in 2024, then sank by 36.6% to $47.4 million in 2025, then slumped by 35.0% to $30.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $30.8 million, $47.4 million, and $62.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.